Progress of ixazomib in treatment of multiple myeloma
10.3760/cma.j.cn115356-20191014-00201
- VernacularTitle:伊沙佐米治疗多发性骨髓瘤研究进展
- Author:
Zhicheng GUO
1
;
Tao WU
;
Hai BAI
Author Information
1. 解放军联勤保障部队第九四○医院 全军血液病中心，兰州 730050
- From:
Journal of Leukemia & Lymphoma
2020;29(8):505-508
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells. Beginning with the use of proteasome inhibitor (PI), the treatment of MM has been significantly improved. Ixazomib is a new generation of PI, the clinical studies have shown that it has good efficacy and safety in frontline therapy, maintenance therapy and treatment of relapsed/refractory MM patients, mainly reflected in prolonging progression-free survival, low peripheral neurotoxicity and long-term medication without accumulated toxicity. This article reviews the mechanism of action, pharmacokinetics, clinical studies and adverse reactions of ixazomib, in order to provide references for the treatment of MM.
